CoChat

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity. We evaluated a novel, fully automated ex vivo DSS platform that uses high-throughput flow cytometry in 54 patients with newly diagnosed or treatment-refractory myeloid neoplasms to evaluate sensitivity (blast cytotoxicity and differentiation) to 74 US Food and Drug Administration–approved or investigational drugs and 36 drug combinations. After piloting the platform in 33 patients, we conducted a prospective feasibility study enrolling 21 patients refractory to hypomethylating agents (HMAs) to determine whether this assay could be performed within a clinically actionable time frame and could accurately predict clinical responses in vivo. When assayed for cytotoxicity, ex vivo drug sensitivity patterns were heterogeneous, but they defined distinct patient clusters with differential sensitivity to HMAs, anthracyclines, histone deacetylase inhibitors, and kinase inhibitors (P < .001 among clusters) and demonstrated synergy between HMAs and venetoclax (P < .01 for combinations vs single agents). In our feasibility study, ex vivo DSS results were available at a median of 15 days after bone marrow biopsy, and they informed personalized therapy, which frequently included venetoclax combinations, kinase inhibitors, differentiative agents, and androgens. In 21 patients with available ex vivo and in vivo clinical response data, the DSS platform had a positive predictive value of 0.92, negative predictive value of 0.82, and overall accuracy of 0.85. These data demonstrate the utility of this approach for identifying potentially useful and often novel therapeutic drugs for patients with myeloid neoplasms refractory to standard therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020001934

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Distinct patient clusters defined by differential ex vivo drug sensitivity. Heat map shows ex vivo drug sensitivity (red) or resistance (blue) to a panel of 31 unique drugs or drug combinations (rows) in 37 patients with myeloid neoplasms (columns), including 34 patients with MDS and 3 patients with MDS/MPN. Patients were clustered on the basis of differential ex vivo drug sensitivity when assayed for cytotoxicity and blast viability using hierarchical clustering (Euclidean distance metric, Ward linkage criterion). Cell color indicates normalized blast percentage ( z -score transformed) compared with vehicle control. Rows above the heat map indicate relevant clinical and biologic variables and the 3 distinct patient clusters. A higher incidence of ASXL1 mutations ( P 5 .008) and higher IPSS-R scores ( P 5 .02) were observed in cluster 2. IDH, isocitrate dehydrogenase; PARP, poly (ADP ribose) polymerase.
Figure 1 Distinct patient clusters defined by differential ex vivo drug sensitivity. Heat map shows ex vivo drug sensitivity (red) or resistance (blue) to a panel of 31 unique drugs or drug combinations (rows) in 37 patients with myeloid neoplasms (columns), including 34 patients with MDS and 3 patients with MDS/MPN. Patients were clustered on the basis of differential ex vivo drug sensitivity when assayed for cytotoxicity and blast viability using hierarchical clustering (Euclidean distance metric, Ward linkage criterion). Cell color indicates normalized blast percentage ( z -score transformed) compared with vehicle control. Rows above the heat map indicate relevant clinical and biologic variables and the 3 distinct patient clusters. A higher incidence of ASXL1 mutations ( P 5 .008) and higher IPSS-R scores ( P 5 .02) were observed in cluster 2. IDH, isocitrate dehydrogenase; PARP, poly (ADP ribose) polymerase.CC-BY-NC-ND · From the PDF
Figure 2 Patient clusters are associated with distinct ex vivo drug sensitivity profiles. (A) Box-and-whisker plots indicate ex vivo sensitivity to various drug classes for the 3 patient clusters defined in the heat map. Boxes indicate the interquartile range (IQR), whiskers show 1.5 3 IQR, and the diamonds outside of this range are considered outliers. (B) Heat map depicting -log10 false discovery rate for cluster mean comparisons. *Adjusted P , .05; **adjusted P , .01; ***adjusted P , .001.
Figure 2 Patient clusters are associated with distinct ex vivo drug sensitivity profiles. (A) Box-and-whisker plots indicate ex vivo sensitivity to various drug classes for the 3 patient clusters defined in the heat map. Boxes indicate the interquartile range (IQR), whiskers show 1.5 3 IQR, and the diamonds outside of this range are considered outliers. (B) Heat map depicting -log10 false discovery rate for cluster mean comparisons. *Adjusted P , .05; **adjusted P , .01; ***adjusted P , .001.CC-BY-NC-ND · From the PDF
Figure 3 Ex vivo drug screening demonstrates synergy between HMAs and venetoclax. Ex vivo drug sensitivity is shown for 54 patients tested with azacitidine, decitabine, and venetoclax as single agents and for 46 patients tested with venetoclax in combination with azacitidine or decitabine. HMA-venetoclax combinations yielded a greater reduction in blast count compared with single agent therapy with an HMA or venetoclax ( P , .01 for all combinations vs single agents; mixed effects linear model). Patients who were treated with 1 of these agents or combinations and who were evaluable for clinical response are highlighted in green (indicating clinical responders; n 5 8) or in red (indicating nonresponders; n 5 9). The remaining patients are indicated in blue.
Figure 3 Ex vivo drug screening demonstrates synergy between HMAs and venetoclax. Ex vivo drug sensitivity is shown for 54 patients tested with azacitidine, decitabine, and venetoclax as single agents and for 46 patients tested with venetoclax in combination with azacitidine or decitabine. HMA-venetoclax combinations yielded a greater reduction in blast count compared with single agent therapy with an HMA or venetoclax ( P , .01 for all combinations vs single agents; mixed effects linear model). Patients who were treated with 1 of these agents or combinations and who were evaluable for clinical response are highlighted in green (indicating clinical responders; n 5 8) or in red (indicating nonresponders; n 5 9). The remaining patients are indicated in blue.CC-BY-NC-ND · From the PDF
Image 4
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 40

Metadata

Authors
Spinner, M. A., Aleshin, A., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., Gekas, C., Heiser, D., & Greenberg, P. L.
Affiliations
  • Stanford Medicine (US)
  • Notable Labs (United States) (US)
Venue
Blood Advances
Published
2020-06-22
Volume
4
Issue
12
Pages
2768-2778
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3036598834
Cited by
40
References
52
Citations by year
2026: 3 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 12 · 2021: 3
FWCI
3.47
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Society of Hematology
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
Keywords
myeloid neoplasms, myelodysplastic syndrome, acute myeloid leukemia, hypomethylating agents, venetoclax, drug synergy, personalized treatment, high-throughput flow cytometry, combination therapy, histone deacetylase inhibitors, kinase inhibitors, anthracyclines, refractory disease, prediction accuracy
MeSH terms
Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Myelodysplastic Syndromes, Prospective Studies, United States, Leukemia, Myeloid, Acute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. https://app.cochat.ai/papers/10.1182/bloodadvances.2020001934
The paper
Spinner, M. A., Aleshin, A., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., Gekas, C., Heiser, D., & Greenberg, P. L. (2020). Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Advances. https://doi.org/10.1182/bloodadvances.2020001934

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.